An allosteric inhibitor of protein arginine methyltransferase 3.

PRMT3, a protein arginine methyltransferase, has been shown to influence ribosomal biosynthesis by catalyzing the dimethylation of the 40S ribosomal protein S2. Although PRMT3 has been reported to be a cytosolic protein, it has been shown to methylate histone H4 peptide (H4 1-24) in vitro. Here, we report the identification of a PRMT3 inhibitor (1-(benzo[d][1,2,3]thiadiazol-6-yl)-3-(2-cyclohexenylethyl)urea; compound 1) with IC50 value of 2.5 μM by screening a library of 16,000 compounds using H4 (1-24) peptide as a substrate. The crystal structure of PRMT3 in complex with compound 1 as well as kinetic analysis reveals an allosteric mechanism of inhibition. Mutating PRMT3 residues within the allosteric site or using compound 1 analogs that disrupt interactions with allosteric site residues both abrogated binding and inhibitory activity. These data demonstrate an allosteric mechanism for inhibition of protein arginine methyltransferases, an emerging class of therapeutic targets.

[1]  Merlin C. Thomas,et al.  Mechanisms of Disease: pathway-selective insulin resistance and microvascular complications of diabetes , 2005, Nature Clinical Practice Endocrinology &Metabolism.

[2]  L. Pearl,et al.  Insights into histone code syntax from structural and biochemical studies of CARM1 methyltransferase , 2007, The EMBO journal.

[3]  N. Keen,et al.  Structural basis of substrate methylation and inhibition of SMYD2. , 2011, Structure.

[4]  P. Silver,et al.  PRMT3 is a ribosomal protein methyltransferase that affects the cellular levels of ribosomal subunits , 2004, The EMBO journal.

[5]  Valérie Campagna-Slater,et al.  Structural Biology of Human H3K9 Methyltransferases , 2010, PloS one.

[6]  Peter A. Jones,et al.  Epigenetic Modifications as Therapeutic Targets , 2010, Nature Biotechnology.

[7]  Yonghong Xiao,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[8]  M. Bedford,et al.  Histone arginine methylation , 2011, FEBS letters.

[9]  M. Hu,et al.  Specific protein methylation defects and gene expression perturbations in coactivator-associated arginine methyltransferase 1-deficient mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  I. Newsham,et al.  DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo , 2004, Oncogene.

[11]  K. Nagata,et al.  SET-mediated Promoter Hypoacetylation Is a Prerequisite for Coactivation of the Estrogen-responsive pS2 Gene by PRMT1* , 2006, Journal of Biological Chemistry.

[12]  A. Mai,et al.  Novel 3,5-bis(bromohydroxybenzylidene)piperidin-4-ones as coactivator-associated arginine methyltransferase 1 inhibitors: enzyme selectivity and cellular activity. , 2011, Journal of Medicinal Chemistry.

[13]  S. Pang,et al.  Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)--Hit to Lead studies. , 2009, Bioorganic & medicinal chemistry letters.

[14]  Jian Jin,et al.  Targets in Epigenetics: Inhibiting the Methyl Writers of the Histone Code , 2011, Current chemical genomics.

[15]  Albert Jeltsch,et al.  Specificity analysis-based identification of new methylation targets of the SET7/9 protein lysine methyltransferase. , 2011, Chemistry & biology.

[16]  J. Tang,et al.  PRMT 3, a Type I Protein Arginine N-Methyltransferase That Differs from PRMT1 in Its Oligomerization, Subcellular Localization, Substrate Specificity, and Regulation* , 1998, The Journal of Biological Chemistry.

[17]  B. Volk,et al.  Expression and function of cytochrome p450 in brain drug metabolism. , 2007, Current drug metabolism.

[18]  Wladek Minor,et al.  HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes. , 2006, Acta crystallographica. Section D, Biological crystallography.

[19]  Lang Li,et al.  Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen‐independent status , 2004, Cancer.

[20]  Y. Kaneda,et al.  Histone methyltransferases: regulation of transcription and contribution to human disease , 2010, Journal of Molecular Medicine.

[21]  S. Clarke,et al.  Uncovering the Human Methyltransferasome* , 2010, Molecular & Cellular Proteomics.

[22]  H. Lennernäs,et al.  CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies. , 2001, Journal of pharmaceutical sciences.

[23]  M. Colasanti,et al.  The dual personality of NO. , 2000, Trends in pharmacological sciences.

[24]  K. O. Elliston,et al.  Chemogenetic Analysis of Human Protein Methyltransferases , 2011, Chemical biology & drug design.

[25]  P. Thompson,et al.  Activity-based protein profiling of protein arginine methyltransferase 1. , 2011, ACS chemical biology.

[26]  K. Kish,et al.  Structural basis for CARM1 inhibition by indole and pyrazole inhibitors. , 2011, The Biochemical journal.

[27]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[28]  Xing Zhang,et al.  Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides. , 2003, Structure.

[29]  D. Fliser,et al.  ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  C. Arrowsmith,et al.  Fluorescence-Based Methods for Screening Writers and Readers of Histone Methyl Marks , 2012, Journal of biomolecular screening.

[31]  S. Bode-Böger,et al.  Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. , 2001, Kidney international. Supplement.

[32]  S. Pang,et al.  Pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1). , 2008, Bioorganic & medicinal chemistry letters.

[33]  Robert A. Copeland,et al.  Protein methyltransferases as a target class for drug discovery , 2009, Nature Reviews Drug Discovery.

[34]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[35]  F. Mackenzie,et al.  Crystal Structures of Human Choline Kinase Isoforms in Complex with Hemicholinium-3 , 2010, The Journal of Biological Chemistry.

[36]  P. Vallance,et al.  Cardiovascular Biology of the Asymmetric Dimethylarginine:Dimethylarginine Dimethylaminohydrolase Pathway , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[37]  S. Pang,et al.  Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1). , 2009, Bioorganic & medicinal chemistry letters.

[38]  Xiaodong Cheng,et al.  Crystal structure of the conserved core of protein arginine methyltransferase PRMT3 , 2000, The EMBO journal.

[39]  Eric Therrien,et al.  1,2-Diamines as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1). , 2009, Bioorganic & medicinal chemistry letters.

[40]  B. Ponder,et al.  Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers , 2011, International journal of cancer.

[41]  Mark T Bedford,et al.  Arginine methylation an emerging regulator of protein function. , 2005, Molecular cell.

[42]  M. Person,et al.  Ribosomal protein S2 is a substrate for mammalian PRMT3 (protein arginine methyltransferase 3). , 2005, The Biochemical journal.

[43]  M. Tohyama,et al.  PRMT3 is essential for dendritic spine maturation in rat hippocampal neurons , 2010, Brain Research.

[44]  J. Rommens,et al.  Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy , 1998, Nature Genetics.

[45]  Troy E. Sandberg,et al.  Human Protein Arginine Methyltransferase 7 (PRMT7) Is a Type III Enzyme Forming ω-NG-Monomethylated Arginine Residues* , 2012, The Journal of Biological Chemistry.

[46]  Dino Moras,et al.  Functional insights from structures of coactivator‐associated arginine methyltransferase 1 domains , 2007, The EMBO journal.

[47]  W. Sippl,et al.  Acyl derivatives of p-aminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1. , 2011, Bioorganic & medicinal chemistry.

[48]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[49]  E. Verdin,et al.  The Cellular lysine methyltransferase Set7/9-KMT7 binds HIV-1 TAR RNA, monomethylates the viral transactivator Tat, and enhances HIV transcription. , 2010, Cell host & microbe.

[50]  Shiyin Yee,et al.  In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth , 1997, Pharmaceutical Research.

[51]  P. Artursson,et al.  Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.

[52]  Feng Liu,et al.  A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. , 2011, Nature chemical biology.

[53]  W. Gu,et al.  Methyltransferase Set7/9 regulates p53 activity by interacting with Sirtuin 1 (SIRT1) , 2011, Proceedings of the National Academy of Sciences.

[54]  Or Gozani,et al.  Modulation of p53 function by SET8-mediated methylation at lysine 382. , 2007, Molecular cell.

[55]  Frank Herrmann,et al.  Human protein arginine methyltransferases in vivo – distinct properties of eight canonical members of the PRMT family , 2009, Journal of Cell Science.

[56]  M. Bedford,et al.  Ribosomal Protein rpS2 Is Hypomethylated in PRMT3-deficient Mice* , 2007, Journal of Biological Chemistry.

[57]  S. Mariotto,et al.  Biochemical aspects of nitric oxide. , 2004, Current pharmaceutical design.

[58]  M. Carmo-Fonseca,et al.  Hsp70 Chaperones and Type I PRMTs Are Sequestered at Intranuclear Inclusions Caused by Polyalanine Expansions in PABPN1 , 2009, PloS one.

[59]  S. Yamagishi,et al.  Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy-Friend or foe? , 2011, Pharmacological research.

[60]  Mathieu Lupien,et al.  CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1. , 2008, Cancer research.

[61]  Sardet Claude,et al.  コアクチベータと会合したアルギニンメチルトランスフェラーゼ1(CARM1)はサイクリンE1遺伝子の正の制御剤である , 2006 .

[62]  H. Katus,et al.  Expression of nitric oxide related enzymes in coronary heart disease , 2006, Basic Research in Cardiology.

[63]  C. Sardet,et al.  Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene , 2006, Proceedings of the National Academy of Sciences.

[64]  Eric Therrien,et al.  N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1). , 2009, Bioorganic & medicinal chemistry letters.

[65]  E. Wahle,et al.  Unusual Sites of Arginine Methylation in Poly(A)-binding Protein II and in Vitro Methylation by Protein Arginine Methyltransferases PRMT1 and PRMT3* , 1999, The Journal of Biological Chemistry.

[66]  H. Swanson.  Cytochrome P450 expression in human keratinocytes: an aryl hydrocarbon receptor perspective. , 2004, Chemico-biological interactions.

[67]  Y. Dou,et al.  PRMT6-mediated methylation of R2 in histone H3 antagonizes H3 K4 trimethylation. , 2007, Genes & development.

[68]  D. Reinberg,et al.  TILRR, a Novel IL-1RI Co-receptor, Potentiates MyD88 Recruitment to Control Ras-dependent Amplification of NF-κB* , 2009, The Journal of Biological Chemistry.

[69]  H. Ruley,et al.  Arginine N-Methyltransferase 1 Is Required for Early Postimplantation Mouse Development, but Cells Deficient in the Enzyme Are Viable , 2000, Molecular and Cellular Biology.

[70]  Valérie Campagna-Slater,et al.  Structural Chemistry of the Histone Methyltransferases Cofactor Binding Site , 2011, J. Chem. Inf. Model..

[71]  E. Wahle,et al.  Promiscuous Modification of the Nuclear Poly(A)-binding Protein by Multiple Protein-arginine Methyltransferases Does Not Affect the Aggregation Behavior* , 2008, Journal of Biological Chemistry.

[72]  K. Helin,et al.  Histone methyltransferases in cancer. , 2010, Seminars in cell & developmental biology.

[73]  S. Richard,et al.  Arginine Methylation of the Histone H3 Tail Impedes Effector Binding* , 2008, Journal of Biological Chemistry.

[74]  E. Guccione,et al.  Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive , 2007, Nature.